Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Sushil K. Badrising, Vincent van der Noort, Paul Hamberg, Jules L. L. M. Coenen, Maureen J. Aarts, Inge M. van Oort, Alfons J. M. van den Eertwegh, Maartje Los, H. Pieter van den Berg, Hans Gelderblom, Suzan Vrijaldenhoven, Emile D. Kerver, Theo van Voorthuizen, Igle J. de Jong, John B. Haanen, Andries M. Bergman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)267-273
Number of pages7
Issue number5
Publication statusPublished - 2016


  • Cross-resistance
  • Treatment sequence
  • Heavily pretreated patients
  • Time interval
  • Docetaxel
  • Abiraterone
  • Cabazitaxel
  • Radium-223

Cite this